Warning letter
Cadila Healthcare Limited: warning letter of Dec 23, 2015
FDA warning letter 471062 · Center for Drug Evaluation and Research
Key facts
| Reference number | 471062 |
|---|---|
| Company | Cadila Healthcare Limited |
| Subject | CGMP/Active Pharmaceutical Ingredient (API)/Adulterated |
| Issue date | Dec 23, 2015 |
| Posted date | Jan 5, 2016 |
| Issuing office | Center for Drug Evaluation and Research |
| Product type | Drugs |
| CFR sections cited | 211.198(a), 211.192 |
| Inspection city | Sanand |
| Inspection start date | Aug 28, 2014 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: